Objective: Angiogenic peptides like VEGF (vascular endothelial growth factor) and bFGF (basic fibroblast growth factor) have entered clinical trials for coronary artery disease. Attempts are being made to devise clinically relevant means of delivery and to effect site-specific delivery of these peptides to the cardiac tissue, in order to limit systemic side-effects. We characterized the response of the pericardium to delivery of a replication-deficient adenovirus carrying the cDNA for AdCMV. VEGF , and assessed the effect of constrictors were placed on the proximal left circumflex coronary artery of mongrel dogs. Ten days later, 6310 pfu AdCMV. VEGF 165 (n59), AdRSV.b-gal (n59), or saline (n57) were injected through an indwelling pericardial catheter. Transfection efficiency was assessed by X-gal staining. Pericardial and serum VEGF levels were measured serially by ELISA. Maximal myocardial collateral perfusion was quantified with radiolabeled or fluorescent microspheres 28 days after treatment. Results: In AdRSV.b-gal-treated dogs, there was extensive b-gal staining in the pericardium and epicardium, with minimal b-gal staining in the mid-myocardium and endocardium. Pericardial delivery of AdCMV. VEGF resulted in sustained (8-14 day) pericardial transgene expression, with VEGF 165 levels peaking 3 days after infection (.200 ng / ml) and decreasing thereafter. There was no detectable increase in serum VEGF levels. Maximal collateral perfusion, a principal correlate of collateral development and angiogenesis, was equivalent in all groups. Conclusion: Adenoviral-mediated gene transfer is capable of inducing sustained VEGF expression in the pericardium; however, locally targeted 165 pericardial VEGF delivery failed to improve myocardial collateral perfusion in this model.
Introduction
hypoxia-inducible angiogenic factor [3] and a potential tumor angiogenesis factor in vivo [4] . VEGF has been Vascular endothelial growth factor (VEGF) / vascular associated with pathological retinal neovascularization permeability factor (VPF) is a secreted, glycosylated, [5, 6] and intra-ocular expression of VEGF has been dimeric protein that is structurally related to plateletcorrelated with retinal neovascularization [7] . In exderived growth factor (PDGF) [1, 2] . VEGF is an endotheliperimental models of limb ischemia, VEGF has been al cell-specific mitogen that has been identified as a demonstrated to promote angiogenesis and collateral development [8-12] . VEGF has also shown promise for myocardial angiogenesis [13] [14] [15] ; however, parenteral administration of VEGF has been associated with dose-*Corresponding author. Present address: The Johns Hopkins University limiting hypotension [15, 16] and acceleration of injury-induced arterial neointimal accumulation [16] , suggesting silastic catheter was positioned in the left atrial appendage that local targeting of the growth factor may be essential for microsphere injections to assess collateral perfusion. for clinical use.
Multiple side holes were fashioned in the distal 2 cm of a Adenoviral-mediated gene transfer has been used suc-6.6-Fr silastic end hole catheter (Bard Access Systems, cessfully to transfer genes to mammalian tissues, and Salt Lake City, UT), and the catheter was secured in the preliminary studies have demonstrated the feasibility of pericardial space. The pericardium was carefully approxiefficient gene transfer to the pericardial sac. [17] . In an mated, and the chest was closed in layers. The termini of attempt to target VEGF protein delivery to cardiac tissues the two catheters were positioned in the subcutaneous and to limit systemic side-effects, we employed a secondtissue of the back, the skin was closed, and the dogs were generation adenovirus for transfer of the gene encoding allowed to recover. human VEGF to cardiac cells in vivo. An E1a-deleted replication-deficient recombinant adenoviral vector was 2.2. Integrity of the pericardium utilized in which the gene encoding human VEGF was 165 under the control of the immediate early cytomegalovirus Ten days after surgery, the pericardium and catheter promoter. We exploited the sequestered environment of the were tested for leakage in a pilot dog by injecting 2 ml of pericardial space for site-specific gene transfer, a strategy contrast agent (Hypaque) into the pericardial space under that might preclude unwanted viral dissemination and fluoroscopic guidance. The dye flowed freely in the enable the vector to evade immune surveillance, thereby pericardial space, and no leak was visualized. prolonging transgene expression. The immediate proximity of the epicardial vasculature and developing collateral 2.3. Transduction efficiency of pericardial gene transfer circulation to the pericardial space and pericardial fluid 9 suggested that this mode of VEGF delivery might lead to
In one dog, 6310 pfu AdRSV.b-gal was instilled into enhancement of myocardial angiogenesis while limiting the pericardial cavity. This gene encodes nuclear-targeted systemic effects.
bacterial b-galactosidase. Myocardium, pericardium, lung, Using a b-gal marker gene, our first goal was to intestine, kidney, gonad, brain, liver, and spleen were determine the anatomic distribution of transgene expresharvested 72 h after transfection, and bacterial b-galactosion after intra-pericardial virus administration. Second, we sidase activity was assessed by 5-bromo-4-chloro-3-indoylsought to characterize the magnitude and time course of b-D-galactopyranoside (X-gal) staining. The tissue was VEGF transgene expression and to determine the disembedded in paraffin and 5-mm sections were counter-165 tribution of adenovirus in body fluids. Our third goal was stained with Nucleofast red for microscopic analysis. to determine whether intrapericardial VEGF gene transfer was capable of improving myocardial collateral perfusion 2.4. Gene expression: serum and pericardial VEGF in a well-characterized canine model of progressive corlevels onary occlusion.
To establish the ability of transduced tissue to secrete VEGF and to assess the time course of protein secretion, 2. Methods recombinant VEGF protein production was quantified by ELISA in six animals (three VEGF-treated, three controls). The experimental protocol was approved by the Animal Samples of pericardial fluid (withdrawn from the indwelCare and Use Committee of the National Heart, Lung, and ling catheter) and serum samples (forelimb venous puncBlood Institute, and conducted in accordance with the ture) were collected serially: before treatment, and on pressure and withdrawal of arterial reference samples. clumping, detachment, cell lysis, and intra-nuclear basoArterial pressure and the electrocardiogram were recorded philic or amphophilic inclusion bodies. Ad5 CMV-LacZ continuously. Maximal coronary vasodilatation was ininoculated into normal canine urine served as the positive duced by infusing chromonar 8 mg / kg (Hoechst-Roussel control; the negative control consisted of a ten-fold diluPharmaceuticals) into the left atrial catheter over 30 min as tion of normal canine urine.
we have done previously [13, 16] . After infusion of performed in duplicate with two labels ( Ce and Nb for Selection of the dose was based on our pilot experiments radiolabeled microspheres; dual-labeled red, orange or and previous studies [20] . Aliquots of stock violet dyes for fluorescent microspheres), and the results AdCMV. VEGF and AdRSV.b-gal (63) (generously were averaged. The dogs were heparinized (5000 Units 165 10 supplied by GenVec, Inc., Rockville, MD), 10 pfu i.v.), killed with an overdose of sodium pentobarbital and (volume 1 ml) were stored at 2808C until used. The viral KCl, and the myocardium was perfusion-fixed with 10% solution was diluted in 3 ml serum-free EBM medium buffered formaldehyde at physiologic pressure. The heart (Clonetics, San Diego, CA) immediately prior to adminiswas cut into 7-mm transaxial slices and examined macrotration. Using sterile technique, the viral solution was scopically for the presence of infarcts or patchy areas of injected transcutaneously through the infusion port of the fibrosis. For radiolabeled microsphere analyses, the two pericardial catheter, followed by 2 ml of EBM medium.
central left ventricular slices were divided into 16 wedges and ranked with respect to perfusion. The four wedges 2.8. Analysis of organ toxicity with the highest perfusion were selected to represent the normal zone (NZ); the four wedges with the most comproUsing aseptic technique, an 18-gauge needle was inmised perfusion were selected to represent the collateral serted into the subcutaneous port of the pericardial catheter zone (CZ) as we have done previously [13, 16] . For on a regular basis to quantify and remove, if necessary, fluorescent microsphere analyses, only the central slice accumulated pericardial fluid. If less than 20 ml of was analyzed. Using a dual wavelength detector system, pericardial fluid could be withdrawn, it was returned to the intact microspheres from tissue digests were characterized pericardial space. Larger effusions were evacuated to with respect to dye ratio and counted using a coulter Mean NZ and CZ perfusion were calculated from the duplicate perfusion measurements, and maximal collateral perfusion was expressed in relative terms as the CZ / NZ perfusion ratio as we have done previously [13, 16] . The CZ / NZ ratio was defined prospectively as the primary study endpoint. Data are expressed as mean6S.E.M.
Results
Twenty-six of 32 dogs completed the studies. Five dogs died suddenly, 2-15 days after ameroid placement, presumably from sudden coronary occlusion or ameroid-induced coronary artery spasm. Two of five dogs expired before initial gene transfer. Of the three animals that died after gene transfer, one had received AdCMV. VEGF and tion; autopsy revealed 250 ml of fluid in the pericardial space and death was attributed to cardiac tamponade. There was discordance between the two measurements of virus-treated groups. Transgene expression was evident 24 myocardial perfusion in one dog, and it was excluded from h after viral infection, and peak pericardial VEGF levels the analysis prior to breaking the study code. Thus, were recorded on day 3 in AdCMV. VEGF-treated dogs perfusion measurements are reported for 25 dogs. One (.200 ng / ml). VEGF levels diminished to¯15 ng / ml by additional dog was used for a determination of in vivo day 8, and tapered off gradually thereafter, such that the b-gal transfection efficiency.
total duration of the response was¯14 days (Fig. 3) . Serum VEGF levels did not increase from pretreatment 3. There was no detectable shedding of virus in the fecal or after infection, tapering off thereafter (Fig. 1) (Fig. 2a) and epicardium (Fig. 2b) . Reporter tamponade with a 250-ml hemorrhagic inflammatory effugene transfer was almost entirely restricted to pericardial sion (elevated polymorphonuclear leucocyte count). The and epicardial cells, with scattered sparse expression in the aspirated fluid was cultured in all cases and found to be mid-myocardium, and no detectable staining of the endofree of bacterial infection. None of the AdRSV.b-galcardium.
treated animals had significant effusions (.20 ml).
Pericardial and serum VEGF levels 3.6. Collateral conductance and CZ /NZ perfusion ratios
Pre-treatment VEGF levels were negligible in both Microsphere perfusion determinations, performed in duplicate, showed excellent intra-animal agreement. In the For the critical comparison between the AdRSV.b-gal and normally-perfused territory of the left anterior descending AdCMV. VEGF groups, mean CZ / NZ ratios were 165 coronary artery, maximal coronary conductance was simi-0.3660.03 and 0.3660.04, respectively. lar in the three treatment groups on day 28 (Table 1) . Maximal collateral conductance in the territory of the 3.7. Histological analysis occluded LCx was similar in all groups, and the CZ / NZ ratios were virtually identical in the three treatment groups.
No cytopathic effects were grossly evident in the reasons, we considered gene transfer as a means to bring pericardium or surrounding lungs at the time of tissue about localized myocardial targeting of VEGF, with exharvest, i.e. structures were relatively free of adhesions.
tended delivery of protein to maximize therapeutic effect.
X-gal staining of distant organs did not reveal b-gal
Arterial gene transfer is currently under investigation as expression in any tissue. a means to promote therapeutic angiogenesis in ischemic Histological analysis of the heart revealed no difference limbs, utilizing a hydrogel polymer-coated balloon to between treatment groups in the degree of vascularity, establish direct contact of naked VEGF plasmid cDNA fibrosis or inflammation or thrombosis. Microscopic anwith the arterial wall [24, 25] . This technique has important giomas or hemangiomas were not noted.
limitations due to the inherent inefficiency of direct arterial plasmid gene transfer, a problem that is magnified in atherosclerotic arteries. Moreover, in at least one inves-4. Discussion tigation in which this technique has been successful, a generalized drug effect was observed, [26] suggesting that VEGF is one of several angiogenic heparin-binding limited, locally targeted therapy may not be attainable with growth factors reported to promote collateral development this method. Several investigators have demonstrated that second quantities of the VEGF peptide administered in previous generation adenoviral vectors function efficiently as gene studies in which it was found to be effective. We observed delivery vehicles in vivo [27, 28] , superior in efficiency to peak steady state VEGF levels of approximately 200 ng / ml plasmid DNA injection [29] . Successful intramyocardial in a pericardial fluid volume of roughly 200 ml: an injection of adenoviral vectors has been demonstrated in estimated mass of approximately 40 mg. Considering that mammals [20, 32] . Recently, intracoronary injection of a the pericardial VEGF concentration decreased to 15 ng / ml recombinant adenovirus expressing human FGF-5 was by day 8, the total quantity of VEGF produced in the shown to increase perfusion and contractile function in the present investigation, integrated over the 2-week period of ischemic porcine heart [30] . Intracoronary gene delivery expression, was probably an order of magnitude less than appears promising, although the potential for viral dissemithe cumulative injected dose we previously found to be nation to non-target tissues poses an important concern.
effective (45 mg / day320 doses5900 mg) [13] . On the Viral receptors are found on the surface of a variety of cell other hand, the quantity of VEGF produced in this types, and generalized dissemination of angiogenic genes experiment significantly exceeded the dose used by Harada could lead to undesirable neovascularization in sites such et al. [31] .
wall We evaluated pericardial VEGF gene transfer as a means to target the myocardium and avoid the potential
The presence of VEGF in the pericardial space presents problems associated with systemic adenoviral disseminathe growth factor to the abluminal (rather than the luminal) tion. E1a-deleted replication-deficient adenovirus with the side of the vasculature. Though this unconventional mode gene encoding VEGF was delivered to the pericardial of VEGF administration might be responsible for its lack 165 space. We hypothesized that the pericardium might provide of effect in this experiment, Harada et al. [14] found an abundant surface area for gene transfer as well as an perivascular infusion of VEGF (mixed with heparin) to be inherent means for viral containment. Furthermore, the effective, a method that also delivered VEGF to the limited pericardial volume of distribution would tend to abluminal aspect of the vasculature. Two key differences favor gene transfer by maximizing the concentration of the between the present and previous investigations should be virus, and would serve to maintain the concentration of the underscored: Harada et al.
[14] used a longer duration of expressed VEGF gene product at a relatively high level. In infusion (4 weeks, although VEGF potency was reduced by essence, the pericardium might function as a paracrine a factor of 2.5 at the end of their study), and VEGF and organ, producing high localized VEGF levels in direct heparin were co-administered in their study. VEGF is a apposition to the epicardial arteries and developing collaheparin-binding growth factor, and the interactions beterals, leading to myocardial angiogenesis.
tween VEGF and heparin have not been well-characterized The pericardial space has been evaluated previously as a in vivo [34, 35] . reservoir for angiogenic growth factor delivery [32, 33] . Pericardial injection of basic fibroblast growth factor has 4.3. Preservation of VEGF activity across species been reported to enhance myocardial angiogenesis [36] and limit infarct size after coronary embolization [37] In the present study, we demonstrated that gene transfer in vitro [13] . to non-replicating pericardial and epicardial cells using recombinant adenovirus vectors resulted in acceptable gene 4.4. Role of inflammation targeting efficiency and expression of the VEGF transgene over a 10-14-day period. Although this strategy was It is plausible that adenoviral-related inflammation had a highly effective in directing pericardial VEGF expression, negative influence on collateral development in this study. the pericardial VEGF so produced was ineffective in
We found, however, that collateral function was not promoting collateral development. There are a number of depressed in AdRSV.b-gal-treated animals (relative to potential explanations for the apparent lack of effect. saline-treated controls), suggesting that this was not the case. Animals treated with the b-gal virus did not develop 4.1. Adequacy of VEGF production hemodynamically significant pericardial effusions, but large effusions were encountered consistently in It is worthwhile to contrast the calculated mass of VEGF AdCMV. VEGF-treated dogs, requiring drainage to avert produced by gene transfer in the present experiment to the hemodynamic compromise. Leucocyte counts were gener- production, however, myocardial collateral perfusion was number of studies on the effects of VEGF on myocardial The optimal VEGF dose, the timing, duration, and route of Moreover, it remains to be determined whether pericardial 
